The Risks of Compounded Weight Loss Drugs: A Look at Hims & Hers Controversial Strategy

The weight loss drug market, dominated by GLP-1 agonists from companies like Novo Nordisk and Eli Lilly, is facing competition. While some companies are investing in developing their own GLP-1 drugs, Hims & Hers Health is taking a different approach by offering compounded versions of existing medications like Ozempic. This strategy, however, is risky. Similar to counterfeit goods, compounded medications may contain different ingredients and lack the quality control of FDA-approved drugs. While compounded GLP-1 injections might seem like a cheaper alternative to expensive brand-name drugs, the lack of FDA oversight regarding their safety and effectiveness raises concerns.